Decay Accelerating Factor and B cell Immunity
衰变加速因子和 B 细胞免疫
基本信息
- 批准号:10623288
- 负责人:
- 金额:$ 42.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-06-17 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAlternative Complement PathwayAntibodiesAntibody AffinityAntibody FormationAntibody ResponseAntibody titer measurementAntigensAutoimmuneAutoimmunityB Cell ProliferationB-Cell ActivationB-LymphocytesBCL6 geneBiologicalBiologyC3AR1 geneC5a anaphylatoxin receptorCD55 AntigensCell SurvivalCell surfaceCellular biologyChromosome 1ComplementComplement 3 ConvertaseComplement 3aComplement 3d ReceptorsComplement 5aComplement ActivationDataDevelopmentDiseaseDown-RegulationEnhancersEventFollicular Dendritic CellsFutureGenerationsGenesGenetic TranscriptionHumoral ImmunitiesImmune responseImmunityImmunizationImmunoglobulin Somatic HypermutationImpairmentInfectionLiftingLigationLightLinkMediatingMediatorMemory B-LymphocyteModelingMolecularMusOutcomeOutputPIK3CG genePathogenicityPhysiologicalPlasma CellsProcessProductionReactionReagentReceptor SignalingRegulationRepressionResearchRoleSignal PathwaySignal TransductionSolidStructure of germinal center of lymph nodeSystemT-LymphocyteTestingTransgenic OrganismsTransplantationVaccineschronic graft versus host diseasecomplement C3d,gcomplement pathwaygene repressiongenetic regulatory proteinin vivoinsightlymphoid structuresmembernovelorgan transplant rejectionoverexpressionpathogenpreventprogramspromoterreceptorresponserestrainttransmission processvaccine strategy
项目摘要
Project Summary
Humoral immunity crucially protects against pathogens but can function as a pathogenic mediator of multiple
autoimmune and alloimmune disease processes, the latter including chronic graft vs. host disease and
antibody-mediated solid organ transplant rejection. Development of antigen-specific antibody responses
requires T cell-dependent B cell activation and the formation of germinal centers (GC), transient lymphoid
structures where somatic hypermutation and affinity maturation events result in the generation of high affinity,
antibody-producing plasma cells (PC) and memory B cells (Bmem). The physiological signals that control GC
formation and GC B cell fates are incompletely characterized. Our preliminary data identify a previously
unappreciated role for decay accelerating factor (DAF or CD55), a cell surface-expressed complement
regulatory protein, in controlling GC reactions and their resultant output, the production of PC and Bmem. Our
data support the hypothesis that optimal GC function requires downregulation of cell surface expressed DAF
on responding B cells, a process that lifts restraint on local, alternative pathway complement activation and
facilitates C3- and C5-convertase formation and production of C3 and C5 cleavage products. This process
promotes C3a/C3aR1 and C5a/C5aR1 ligations on GC B cells, which would in turn transduce signals
controlling GC B cell proliferation, survival, somatic hypermutation, and/or affinity maturation, and as a
consequence, influence differentiation into memory B cells and/or plasma cells. We will test this paradigm-
shifting hypothesis using unique biological reagents and through 3 interactive aims: 1) To determine the effects
of B cell-expressed DAF, C3aR1 and C5aR1 on T cell-dependent humoral immune responses and distinguish
them from the effects of B cell-expressed CD21. 2) To determine the cellular and molecular mechanisms
through which DAF downregulation and enhanced signaling through C3aR1/C5aR1 in B cells drive affinity
maturation. 3) To determine the molecular basis of DAF downregulation on B cells. This comprehensive
analysis performed by a multi-PI team with expertise in complement biology (Heeger) and B cell biology
(Dominguez-Sola) is likely to provide new insight into fundamental mechanisms of GC dynamics and function.
The results have the potential to guide second order studies aimed at exploiting the complement/B cell axis to
either inhibit development of pathogenic B cell responses (e.g. in transplantation or autoimmunity) or augment
B cell response (e.g. in response to vaccines).
项目摘要
体液免疫对病原体具有至关重要的保护作用,但也可以作为多发性硬化症的致病媒介。
自身免疫和同种异体免疫疾病过程,后者包括慢性移植物抗宿主疾病和
抗体介导的实体器官移植排斥反应。抗原特异性抗体反应的研究进展
需要依赖T细胞的B细胞的激活和生发中心(GC)、暂时性淋巴的形成
其中体细胞超突变和亲和力成熟事件导致产生高亲和力的结构,
产生抗体的浆细胞(PC)和记忆B细胞(Bmem)。控制GC的生理信号
其形成和GC B细胞的命运尚不完全清楚。我们的初步数据显示,之前
衰变加速因子(DAF或CD55)是一种细胞表面表达的补体,其作用未被重视
调节蛋白,控制GC反应及其产物PC和Bmem的产生。我们的
数据支持这样的假设,即最佳的GC功能需要下调细胞表面表达的DAF
在反应性B细胞上,这一过程解除了对局部替代途径补体激活的限制,并
促进C3-和C5-转换酶的形成和C3和C5裂解产物的产生。这一过程
促进GC B细胞上C3a/C3aR1和C5a/C5aR1的连接,进而转导信号
控制GC B细胞的增殖、存活、体细胞超突变和/或亲和力成熟,并作为一种
结果,影响分化为记忆B细胞和/或浆细胞。我们将测试这一范例-
使用独特的生物试剂并通过3个交互目的改变假说:1)确定效果
B细胞表达的DAF、C3aR1和C5aR1对T细胞依赖性体液免疫应答的影响及区别
它们来自于B细胞表达CD21的效应。2)确定细胞和分子机制
B细胞中DAF下调和通过C3aR1/C5aR1增强信号驱动亲和力
成熟。3)探讨DAF下调B细胞功能的分子基础。这一全面的
由具有补体生物学(Heeger)和B细胞生物学专业知识的多PI团队执行的分析
(Dominguez-Sola)可能为GC动力学和功能的基本机制提供新的见解。
这些结果有可能指导旨在利用补体/B细胞轴的二级研究
抑制致病性B细胞反应的发展(例如,在移植或自身免疫中)或增强
B细胞反应(如对疫苗的反应)。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Cleaving It All Behind: ADAMTS7 Degrades Factor H.
- DOI:10.1681/asn.0000000000000030
- 发表时间:2023-02
- 期刊:
- 影响因子:0
- 作者:P. Heeger;P. Cravedi
- 通讯作者:P. Heeger;P. Cravedi
Effects of the complement system on antibody formation and function: implications for transplantation.
- DOI:10.1097/mot.0000000000001002
- 发表时间:2022-10-01
- 期刊:
- 影响因子:2.2
- 作者:Cumpelik, Arun;Heeger, Peter S.
- 通讯作者:Heeger, Peter S.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David Dominguez-Sola其他文献
David Dominguez-Sola的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David Dominguez-Sola', 18)}}的其他基金
Decay Accelerating Factor and B cell Immunity
衰变加速因子和 B 细胞免疫
- 批准号:
10406250 - 财政年份:2019
- 资助金额:
$ 42.38万 - 项目类别:
Role of FOXO1 mutations in the pathogenesis of B cell non-Hodgkin lymphomas
FOXO1突变在B细胞非霍奇金淋巴瘤发病机制中的作用
- 批准号:
10334435 - 财政年份:2018
- 资助金额:
$ 42.38万 - 项目类别:
Role of FOXO1 mutations in the pathogenesis of B cell non-Hodgkin lymphomas
FOXO1突变在B细胞非霍奇金淋巴瘤发病机制中的作用
- 批准号:
10087895 - 财政年份:2018
- 资助金额:
$ 42.38万 - 项目类别:
ROLE OF REPLICATION STRESS DURING MYC-DEPENDENT LYMPHOMAGENESIS
复制应激在 MYC 依赖性淋巴细胞生成过程中的作用
- 批准号:
8146177 - 财政年份:2010
- 资助金额:
$ 42.38万 - 项目类别:
ROLE OF REPLICATION STRESS DURING MYC-DEPENDENT LYMPHOMAGENESIS
复制应激在 MYC 依赖性淋巴细胞生成过程中的作用
- 批准号:
7962386 - 财政年份:2010
- 资助金额:
$ 42.38万 - 项目类别:
Role of Replication Stress during Myc-dependent Lymphomagenesis
复制应激在 Myc 依赖性淋巴瘤发生过程中的作用
- 批准号:
8785173 - 财政年份:2010
- 资助金额:
$ 42.38万 - 项目类别:
Role of Replication Stress during Myc-dependent Lymphomagenesis
复制应激在 Myc 依赖性淋巴瘤发生过程中的作用
- 批准号:
8819518 - 财政年份:2010
- 资助金额:
$ 42.38万 - 项目类别:
相似海外基金
Alternative complement pathway regulation of beta cell homeostasis
β细胞稳态的替代补体途径调节
- 批准号:
10221291 - 财政年份:2020
- 资助金额:
$ 42.38万 - 项目类别:
Alternative complement pathway regulation of beta cell homeostasis
β细胞稳态的替代补体途径调节
- 批准号:
9886859 - 财政年份:2020
- 资助金额:
$ 42.38万 - 项目类别:
Alternative complement pathway regulation of beta cell homeostasis
β细胞稳态的替代补体途径调节
- 批准号:
10080727 - 财政年份:2020
- 资助金额:
$ 42.38万 - 项目类别:
Alternative complement pathway regulation of beta cell homeostasis
β细胞稳态的替代补体途径调节
- 批准号:
10530710 - 财政年份:2020
- 资助金额:
$ 42.38万 - 项目类别:
Alternative complement pathway regulation of beta cell homeostasis
β细胞稳态的替代补体途径调节
- 批准号:
10306383 - 财政年份:2020
- 资助金额:
$ 42.38万 - 项目类别:
Elucidation of the activation mechanism of the complement factor MASP-3 of the alternative complement pathway
补体旁路途径补体因子MASP-3激活机制的阐明
- 批准号:
19K07610 - 财政年份:2019
- 资助金额:
$ 42.38万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Alternative Complement Pathway and Hemocompatibility of Nanosurfaces
纳米表面的替代补体途径和血液相容性
- 批准号:
10212959 - 财政年份:2016
- 资助金额:
$ 42.38万 - 项目类别:
The Alternative Complement Pathway and Hemocompatibility of Nanosurfaces
纳米表面的替代补体途径和血液相容性
- 批准号:
10053157 - 财政年份:2016
- 资助金额:
$ 42.38万 - 项目类别:
The alternative complement pathway and hemocompatibility of nanosurfaces
补体替代途径和纳米表面的血液相容性
- 批准号:
9274284 - 财政年份:2016
- 资助金额:
$ 42.38万 - 项目类别:
The Alternative Complement Pathway and Hemocompatibility of Nanosurfaces
纳米表面的替代补体途径和血液相容性
- 批准号:
10653068 - 财政年份:2016
- 资助金额:
$ 42.38万 - 项目类别:














{{item.name}}会员




